Research Article

Olanzapine 5mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy

Jun Wang,1,2 Tao Li,2 Li-E Lin,2 Qin Lin,2 and San-Gang Wu2

1Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
2Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China

Correspondence should be addressed to Qin Lin; linqin05@163.com and San-Gang Wu; wusg@xmu.edu.cn

Received 7 December 2021; Revised 16 February 2022; Accepted 11 March 2022; Published 20 March 2022

Academic Editor: Weiren Luo

Copyright © 2022 Jun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To explore the efficacy and safety of adding olanzapine (5 mg or 10 mg) to 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA), neurokinin-1 receptor antagonists (NK1 RA), and dexamethasone for nausea and vomiting in patients with nasopharyngeal carcinoma (NPC) receiving cisplatin-based concurrent chemoradiotherapy. Methods. Patients receiving olanzapine 5 mg or 10 mg combined with 5-HT3 RA, NK1 RA, and dexamethasone during the cisplatin-based concurrent chemoradiotherapy were included. The primary endpoint was the complete response (CR) (no vomiting) rate, and the secondary endpoint was the incidence of no nausea. Results. A total of 150 chemotherapy cycles were administrated for 88 patients (75 in the olanzapine 5 mg group and 75 in the olanzapine 10 mg group). The proportions of CR in the olanzapine 5 mg group were comparable to those in the olanzapine 10 mg group in acute (93.3% vs. 94.7%, P = 0.731), delayed (76% vs. 78.7%, P = 0.697), and overall phase (73.3% vs. 77.3%, P = 0.570). Moreover, no nausea rates were also comparable between the two groups in acute (76% vs. 78.7%, P = 0.697), delayed (54.7% vs. 60%, P = 0.509), and overall period (50.7% vs. 57.3%, P = 0.111). Regarding the adverse effects, the incidence of somnolence in the 10 mg group (58.6%) was significantly higher than that in the 5 mg group (41.3%) (P = 0.034), while constipation (20.0% vs. 24.0%, P = 0.554) and hiccups (9.3% vs. 10.6%, P = 0.785) rates were comparable in two groups. Conclusions. Patients receiving olanzapine plus standard antiemetic therapy has excellent antiemetic effect in NPC patients receiving cisplatin-based concurrent chemoradiotherapy, and patients with olanzapine 5 mg have a similar antiemetic effect and lower adverse effects compared with those with olanzapine 10 mg.

1. Introduction

Nasopharyngeal carcinoma (NPC) is a subtype of head and neck malignant tumor characterized by unique geographical distribution in Southern China, Southeast Asia, and North Africa [1]. Approximately 70-80% of the NPC patients are diagnosed with stage III-IVA disease, and guidelines for current clinical practice recommend that platinum-based induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) or platinum-based CCRT + adjuvant chemotherapy serves as the standard management in this disease, with a 5-year overall survival rate about 85% [2–4].

Cisplatin, as a highly emetogenic drug, is recommended for a total dose of 100 mg/m² triweekly or 40 mg/m² weekly in patients with NPC receiving CCRT [3]. However, several studies demonstrated that patients receiving a standard dose of cisplatin had higher adverse effects, especially gastrointestinal reactions and hematological toxicities, and that approximately 6%-16% of the patients uncompleted the scheduled courses or reduced the dose of chemotherapy, severely affecting the therapeutic effect [5–7]. Chemotherapy-induced nausea and vomiting (CINV), as a common adverse effect of cisplatin, with an estimated prevalence of 70–80%, seriously affect the quality of life, treatment compliance, and even...
therapeutic efficacy of the patients with cancer, including NPC [8–10]. A previous study has found that 35.7% of the NPC patients receiving CCRT suffered CINV [11]. The international guidelines established by the American Society of Clinical Oncology, Multinational Association of Supportive Care in Cancer, and the European Society of Medical Oncology have recommended a combination of olanzapine 10 mg with 5-hydroxytryptamine type 3 receptor antagonists (5-HT₃ RA), neurokinin-1 receptor antagonists (NK₁ RA), and dexamethasone against CINV in cancer patients receiving highly emetogenic chemotherapy, while olanzapine 5-10 mg was suggested in National Comprehensive Cancer Network guideline [12–14].

Olanzapine is an atypical antipsychotic drug that blocks serotonin receptors (5HT₂₅, 5HT₂₆, 5HT₃, 5-HT₆), dopamine receptors (D₁, D₂, D₄), histamine H1 receptors, α₁ adrenergic receptors, and muscarinic receptors [15–17]. Therefore, the US Food and Drug Administration (FDA) has approved it for the treatment of psychotic disturbance [15]. D₂ dopamine receptor and 5HT₃ serotonin receptor appear to correlate with nausea and vomiting; thus, olanzapine is also applied for the prevention of CINV in cancer patients receiving highly emetogenic chemotherapy [18]. Nevertheless, olanzapine still has inevitable adverse effects, including somnolence, constipation, dry mouth, and hiccups [19]. To our knowledge, there is no study exploring the efficacy of the patients with cancer, including NPC [8–10]. A previous study has found that 35.7% of the NPC patients receiving CCRT suffered CINV [11]. The international guidelines established by the American Society of Clinical Oncology, Multinational Association of Supportive Care in Cancer, and the European Society of Medical Oncology have recommended a combination of olanzapine 10 mg with 5-hydroxytryptamine type 3 receptor antagonists (5-HT₃ RA), neurokinin-1 receptor antagonists (NK₁ RA), and dexamethasone against CINV in cancer patients receiving highly emetogenic chemotherapy, while olanzapine 5-10 mg was suggested in National Comprehensive Cancer Network guideline [12–14].

Olanzapine is an atypical antipsychotic drug that blocks serotonin receptors (5HT₂₅, 5HT₂₆, 5HT₃, 5-HT₆), dopamine receptors (D₁, D₂, D₄), histamine H1 receptors, α₁ adrenergic receptors, and muscarinic receptors [15–17]. Therefore, the US Food and Drug Administration (FDA) has approved it for the treatment of psychotic disturbance [15]. D₂ dopamine receptor and 5HT₃ serotonin receptor appear to correlate with nausea and vomiting; thus, olanzapine is also applied for the prevention of CINV in cancer patients receiving highly emetogenic chemotherapy [18]. Nevertheless, olanzapine still has inevitable adverse effects, including somnolence, constipation, dry mouth, and hiccups [19]. To our knowledge, there is no study exploring the efficacy of olanzapine 5 mg or 10 mg plus triple combination on the control of CCRT-induced nausea and vomiting.

2. Materials and Methods

2.1. Patient Selection. The data was prospectively collected from the Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University between Apr 2018 and May 2019. Patients meeting the following criteria were eligible: (1) pathologically diagnosed with NPC; (2) receiving cisplatin-based CCRT; (3) not using the drugs that affect the result of the study, such as 5-HT₃ RA, NKₑ RA, and corticosteroids, within 48 h before treatment; (4) Eastern Cooperative Oncology Group performance status of 0–2; and (5) providing written informed consents. Patients not receiving CCRT or receiving noncisplatin CCRT regimens were excluded. We also excluded the patients with the following severe comorbidities: unstable angina, myocardial infarction, cerebral infarction, or allergic to olanzapine, which might be intolerable to olanzapine. TNM staging was evaluated using the 8th edition American Joint Committee on Cancer/Union for International Cancer Control staging system (T-tumor, N-node, M-metastasis). This study was approved by the ethics committee of the First Affiliated Hospital of Xiamen University (Approved number: XMYY-2021KY053).

2.2. Treatment. A total of 150 chemotherapy cycles were administrated for 88 NPC patients between Apr 2018 and May 2019. Of the patients, 70.5% (n = 62) received 2-3 cycles of IC, including TPF (docetaxel, cisplatin, and 5-fluorouracil), TP, or GP (gemcitabine, cisplatin) regimens. Then patients were scheduled to receive CCRT within 3-4 weeks from the initiation of the last cycle of IC. Cisplatin 100 mg/m² was given intravenously on days 1 (the day radiotherapy began) and 22 (the day irradiating for about 16 times) concurrently with radiotherapy. Intensity-modulated radiotherapy technique was used for radiotherapy with a prescribed dose of gross target volume: 70 grays (Gy) in 32 fractions to the nasopharynx and 66 Gy in 32 fractions to the neck lymph nodes, 5 days per week, for 6-7 weeks.

All patients received a four-drug combination antiemetic regimen consisting of tropisetron (5-HT₃ RA), aprepitant (NK₁ RA), dexamethasone, and olanzapine. Tropisetron 5 mg was administered 30-60 minutes before chemotherapy (intravenously on day 1, orally on days 2-3). Aprepitant was orally administered 60-90 minutes before chemotherapy (125 mg on day 1, 80 mg on days 2-3). Dexamethasone 10 mg was intravenously administered 30-60 minutes before chemotherapy on days 1-3. Olanzapine was randomly administered orally at a dose of 5 mg or 10 mg once per night on days 1-5. The participants could be recruited repeatedly during any CCRT cycles.

2.3. Assessment Procedure. The primary endpoint of this study was complete response (CR) (no vomiting) rate, defined as no emesis and rescue medication in acute (0-24 hours after the initiation of cisplatin), delayed (24-120 hours after the initiation of cisplatin), and overall phase (0 to 120 hours after the initiation of cisplatin). The secondary endpoint was the incidence of no nausea, defined as a visual analog scale (VAS) of 0 in acute, delayed, and overall phases.

The data of daily episodes of vomiting, degrees of nausea, and use of antiemetic drugs were collected from medical records from the initiation of cisplatin (day 1) to day 5. Degrees of nausea were daily assessed using VAS (scale ranging from 0 to 10, with 0 for no nausea and 10 for the maximal level of nausea). The adverse effects were evaluated by investigators and patients, according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (available at https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).

2.4. Statistical Analysis. Chi-square test was applied to compare possible differences of CR and no nausea rates in the acute, delayed, and overall period between olanzapine 5 mg and 10 mg groups. Excel was used to paint the histogram for the percentage of CR and no nausea from day 1 to 5. The percentages of antiemetic-related adverse effects were computed according to the CTCAE version 4.0. IBM SPSS (version 22.0, IBM Corporation, Armonk, NY, USA) was used for statistical analysis, and a $P < 0.05$ was defined as significant.

3. Results

3.1. Patient Clinicopathological Characteristics. A total of 88 NPC patients were included in this study. Of these patients,
62 were enrolled at the beginning of the first and the second cycle of cisplatin-based CCRT. In addition, 26 patients were enrolled in the second cycle of cisplatin-based CCRT because they had completed the first cycle of cisplatin-based CCRT prior to the start of the study. Therefore, a total of 150 chemotherapy cycles were administrated in this study. The receipt of olanzapine 5 mg or 10 mg was randomized in each chemotherapy cycle. 5 mg oral olanzapine was administrated in 75 chemotherapy cycles, and 10 mg oral olanzapine was also administrated in 75 chemotherapy cycles. Table 1 shows the detailed information of the study population. The mean age of the patients was 46 years (range, 23-64 years). Male and female patients were accounting for 77.3% (n = 68) and 22.7% (n = 20), respectively. The percentages of patients with smoking history and alcohol consumption were 56.8% and 25%, respectively. In addition, 76 (86.4%), 9 (10.2%), and 3 (3.4%) of the patients had pathological types of undifferentiated nonkeratinizing NPC, differentiated nonkeratinizing NPC, and the mixture of the above two. The majority of patients had T2-3 (68.2%, n = 60), N1-2 (69.3%, n = 61), and M0 stage (94.3%, n = 83). A total of 14 (15.9%), 36 (40.9%), 33 (37.5%), and 5 (5.7%) patients had stage II, III, IVa, and IVb disease.

3.2. Effects. In the olanzapine 5 mg group, the proportions of CR were 93.3%, 92%, 89.3%, 88%, and 85.3% in day 1 daily to day 5, respectively, and the incidence of no nausea was 76%, 66.7%, 66.7%, 70.7%, and 68% in day 1 daily to day 5, respectively (Figure 1). In the ondansetron 2 mg group, the proportions of CR were 94.7%, 93.3%, 90.7%, 89.3%, and 88% in day 1 to day 5, respectively, and the incidence of no nausea were 78.7%, 70.7%, 72%, 73.3%, and 69.3% from day 1 to day 5, respectively (Figure 1).

In addition, the proportions of CR in the olanzapine 5 mg group were comparable to those in the ondansetron 10 mg group in acute (93.3% [n = 70] vs. 94.7% [n = 71], P = 0.731), delayed (76% [n = 57] vs. 78.7% [n = 59], P = 0.697), and overall phase (73.3% [n = 55] vs. 77.3% [n = 58], P = 0.570) (Table 2). Regarding to the secondary end point (no nausea), the proportions of no nausea were also comparable between the two groups in acute (76% [n = 57] vs. 78.7% [n = 59], P = 0.697), delayed (54.7% [n = 41] vs. 60% [n = 45], P = 0.509), and overall period (50.7% [n = 38] vs. 57.3% [n = 43], P = 0.111) (Table 2).

3.3. Adverse Events. We evaluated the common adverse effects (hiccups, somnolence, and constipation) in the treatment of olanzapine. No patients discontinued olanzapine due to treatment-related adverse events. During 0-120 hours after the initiation of olanzapine, somnolence (50.0%, n = 75) was the most common adverse effect in the whole cohort, followed by constipation (22.0%, n = 33) and hiccups (10.0%, n = 15). The majority of the side effects were grade 1 and grade 2, and only one patient suffered grade 3 somnolence. The incidence of somnolence in the olanzapine 10 mg group (58.6%) was significantly higher than that in the olanzapine 5 mg group (41.3%) (P = 0.034), while constipation (20.0% vs. 24.0%, P = 0.554) and hiccups (9.3% vs. 10.6%, P = 0.785) rates were comparable in two groups. The details of the adverse effect distribution in two experimental groups were presented in Table 3.

### Table 1: Characteristics of the study patients (N = 88).

| Variables                  | N   | %   |
|----------------------------|-----|-----|
| Gender                     |     |     |
| Male                       | 68  | 77.3|
| Female                     | 20  | 22.7|
| Age (year)                 |     |     |
| Mean                       | 46  |     |
| Range                      | 23-68|    |
| Smoking history            |     |     |
| Yes                        | 50  | 56.8|
| No                         | 38  | 43.2|
| Alcohol consumption        |     |     |
| Yes                        | 22  | 25  |
| No                         | 66  | 75  |
| Pathological type          |     |     |
| Undifferentiated non-keratinizing carcinoma | 76 | 86.4 |
| Differentiated non-keratinizing carcinoma | 9  | 10.2 |
| Mixed type of above two    | 3   | 3.4 |
| Clinical stage             |     |     |
| II                         | 14  | 15.9|
| III                        | 36  | 40.9|
| IVa                        | 33  | 37.5|
| IVb                        | 5   | 5.7 |
| T stage                    |     |     |
| T1                         | 12  | 13.6|
| T2                         | 20  | 22.7|
| T3                         | 40  | 45.5|
| T4                         | 16  | 18.2|
| N stage                    |     |     |
| N0                         | 4   | 4.6 |
| N1                         | 33  | 37.5|
| N2                         | 28  | 31.8|
| N3                         | 23  | 26.1|
| M stage                    |     |     |
| M0                         | 83  | 94.3|
| M1                         | 5   | 5.7 |
| Induction chemotherapy     |     |     |
| Yes                        | 62  | 70.5|
| No                         | 26  | 29.5|

4. Discussion

To the best of our knowledge, this study was the first to explore the optimum dose of olanzapine (5 mg or 10 mg) combined with triple combination antiemetic therapy against CCRT-induced nausea and vomiting in NPC patients. The result showed that patients receiving olanzapine 10 mg had a comparable antiemetic effect, but a higher incidence of adverse effects (especially somnolence) compared with those treated
with olanzapine 5 mg whether in acute, delayed, or overall phases.

Numerous previous studies had elaborated that the combination of olanzapine 5 mg or 10 mg antiemetic therapy provided a significant improvement against highly emetogenic chemotherapy [14, 16, 20, 21]. However, rare studies compared the efficacy of olanzapine 5 mg and 10 mg in preventing cisplatin-based CINV. A multi-institutional phase II study from Japan including 153 patients (76 in 10 mg group, 77 in the 5 mg group) showed that the CR rate in the 5 mg group was significantly higher than that in the 10 mg group during the delayed phase (85.7% vs. 77.6%, \( P < 0.05 \)) [22]. Their results were different from our study in that the proportion of achieving CR in the 10 mg group was higher than that in the 5 mg group; yet, there was no difference (76% vs. 78.7%, \( P = 0.697 \)). In addition, the CR rates in acute and overall phases in their study were also higher than those in the present study [22]. The possible explanation was that all the included participants in this study were NPC patients who were receiving irradiation of nasopharynx and cervical lymph nodes and cisplatin-based chemotherapy, which made them easier to suffer vomiting than other cancer patients [22]. Additionally, the dose of cisplatin in their study (mean dose 72.9 mg/m\(^2\)) was lower than that in our study (100 mg/m\(^2\)), which could still result in a higher CR rate.

No nausea rate was another effective assessment for the efficacy of antiemetic drugs. In the present study, the

![Complete response](image1)

![No nausea](image2)

**Figure 1:** The incidence of complete response (a) and no nausea (b) in olanzapine 5 mg and 10 mg groups from day 1 (the initiation of cisplatin) to day 5.

**Table 2:** The complete response and no nausea rate and in acute, delayed, and overall phase between two groups.

| Variables                  | Olanzapine 5 mg | Olanzapine 10 mg | \( P \) |
|----------------------------|-----------------|------------------|------|
| Acute phase (0-24 h)       |                 |                  |      |
| Complete response          | 70 (93.3%)      | 71 (94.7%)       | 0.731|
| No nausea                  | 57 (76%)        | 59 (78.7%)       | 0.697|
| Delayed phase (25–120 h)   |                 |                  |      |
| Complete response          | 57 (76%)        | 59 (78.7%)       | 0.697|
| No nausea                  | 41 (54.7%)      | 45 (60%)         | 0.509|
| Overall phase (0–120 h)    |                 |                  |      |
| Complete response          | 55 (73.3%)      | 58 (77.3%)       | 0.570|
| No nausea                  | 38 (50.7%)      | 43 (57.3%)       | 0.111|
percentage of no nausea in the olanzapine 5 mg group was 76%, 54.7%, and 50.7% in acute, delayed, and overall periods, respectively, which were higher than the result from a phase 3 randomized trial conducted by Navari et al. that 73.8% in the acute phase, 42.4% in the delayed phase, and 37.3% in overall phase in the olanzapine 5 mg group [17]. It is worth noting that 89.6% of the patients were of the white race, and only 2.6% were Asians in their study, while all of the patients in our study were Asians. Previous studies have shown that race might have an association with different levels of CINV [23, 24]; hence, the distribution of race might be the reason for the difference. Another study from Navari et al. explored the effect of olanzapine (10 mg), palonosetron, dexamethasone compared to fosaprepitant, palonosetron, and dexamethasone on CCRT-induced nausea and vomiting in locally advanced head and neck or esophageal cancer. They found that CR rate was similar between the treatment arms, while nausea in the delayed and overall periods was significantly improved in those treated with olanzapine compared to those without olanzapine [25]. It is worth noting that triplet-combination regimen with olanzapine 10 mg in the above study had higher no nausea rates in acute (86% vs. 78.7%), delayed (71% vs. 60%), and overall periods (71% vs. 57.3%) compared with four-drug combination regimen with olanzapine 10 mg in our study. The reason might be that the dose of cisplatin they used was lower than ours in CCRT (> 70 mg/m² vs. 100 mg/m²), making the no nausea rates higher than our study [25]. In addition, the proportions of no nausea were comparable between olanzapine 5 mg and 10 mg groups no matter in acute (P = 0.69), delayed (P = 0.51), and overall period (P = 0.11) in our study. Therefore, a four-drug combination regimen with olanzapine 5 mg might be enough in the control of nausea in NPC patients receiving CCRT.

Somnolence is the most common adverse effect associated with olanzapine. Previous studies have shown that sleepiness remained a matter of serious concern in 53.3%-73% of the patients receiving olanzapine 10 mg, which was higher than those treated with olanzapine 5 mg (22.7%-45.5%) [26-28]. In the present study, the incidence of somnolence in olanzapine 5 mg and 10 mg groups was 58.6% and 41.3%, respectively. Among them, grade 1 and grade 2 somnolence in the olanzapine 10 mg group was all higher than that in the olanzapine 5 mg group, and 1 patient receiving olanzapine 10 mg suffered grade 3 somnolence. Our result is consistent with aforementioned studies [22, 26, 27]. To our knowledge, drowsiness greatly impacts the patients’ daily life, including communication, social function, and sleep quality [28, 29]; therefore, based on equiva-
Acknowledgments

We thank all patients who participated in this study. This work was partly supported by the Commission Young and Middle-Aged Talents Training Project of Fujian Health Commission (No. 2019-ZQNBI-25), National Natural Science Foundation of China (No. 81772893), Natural Science Foundation of Fujian Province (No. 2020J01220), and the Key Medical and Health Projects in Xiamen (No. 3502Z20209002).

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] NCCN, NCCN clinical practice guidelines in oncology. Head-and-neck cancers, version 3, 2021. https://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf.

[3] Y. P. Chen, N. Ismaila, M. L. K. Chua et al., “Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline,” Journal of Clinical Oncology, vol. 39, no. 7, pp. 840–859, 2021.

[4] Y. Zhang, L. Chen, G. Q. Hu et al., “Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma,” The New England Journal of Medicine, vol. 381, no. 12, pp. 1124–1135, 2019.

[5] L. Q. Tang, D. P. Chen, L. Guo et al., “Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial,” The Lancet Oncology, vol. 19, no. 4, pp. 461–473, 2018.

[6] X. Lv, X. Cao, W. X. Xia et al., “Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial,” The Lancet Oncology, vol. 22, no. 5, pp. 716–726, 2021.

[7] H. Peng, L. Chen, Y. Zhang et al., “Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial,” The Oncologist, vol. 21, no. 11, pp. 1369–1376, 2016.

[8] W. Wiser and A. Berger, “Practical management of chemotherapy-induced nausea and vomiting,” Oncology, vol. 19, no. 5, pp. 637–645, 2005.

[9] W. Marx, A. L. McCarthy, K. Ried et al., “The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial,” Nutrients, vol. 9, no. 8, p. 867, 2017.

[10] A. Shankar, S. Roy, A. Malik, P. K. Julka, and G. K. Rath, “Prevention of chemotherapy-induced nausea and vomiting in cancer patients,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 15, pp. 6207–6213, 2015.

[11] W. F. Li, N. Y. Chen, N. Zhang et al., “Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial,” International Journal of Cancer, vol. 145, no. 1, pp. 295–305, 2019.

[12] P. J. Hesketh, M. G. Kris, E. Basch et al., ”Antiemetics: American Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 35, no. 28, pp. 3240–3261, 2017.

[13] NCCN, “NCCN clinical practice guidelines in oncology,” Antiemesis, 2021. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.

[14] F. Roila, A. Molassiotis, J. Herrstedt et al., “2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients,” Annals of Oncology, vol. 27, suppl 5, pp. v119–v133, 2016.

[15] F. P. Bymaster, D. O. Calligaro, J. F. Falcone et al., “Radioreceptor binding profile of the atypical antipsychotic olanzapine,” Neuropsychopharmacology, vol. 14, no. 2, pp. 87–96, 1996.

[16] R. M. Navari, “Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting,” European Journal of Pharmacology, vol. 722, pp. 180–186, 2014.

[17] R. M. Navari, R. Qin, K. J. Ruddly et al., “Olanzapine for the prevention of chemotherapy-induced nausea and vomiting,” The New England Journal of Medicine, vol. 375, no. 2, pp. 134–142, 2016.

[18] M. V. Braddock and A. Glode, “Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting,” Journal of the Advanced Practitioner in Oncology, vol. 5, no. 1, pp. 24–29, 2014.

[19] H. Hashimoto, M. Abe, O. Tokuyama et al., “Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 21, no. 2, pp. 242–249, 2020.

[20] V. Vimolchaloa, S. Sakdejyont, P. Wongchanapi et al., “The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy,” International Journal of Clinical Oncology, vol. 25, no. 2, pp. 396–402, 2020.

[21] N. Mizukami, M. Yamauchi, K. Koike et al., “Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study,” Journal of Pain and Symptom Management, vol. 47, no. 3, pp. 542–550, 2014.

[22] T. Yanai, S. Iwasa, H. Hashimoto et al., “A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy,” International Journal of Clinical Oncology, vol. 23, no. 2, pp. 382–388, 2018.

[23] L. Bourdeanu, P. Frankel, W. Yu et al., “Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy,” The Journal of Supportive Oncology, vol. 10, no. 4, pp. 149–154, 2012.

[24] B. A. Hassan and Z. B. Yusoff, “Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race,” Asian Pacific Journal of Cancer Prevention, vol. 11, no. 6, pp. 1523–1527, 2010.
[25] R. M. Navari, C. K. Nagy, J. Le-Rademacher, and C. L. Loprinzi, "Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting," *Journal of Community and Supportive Oncology*, vol. 14, no. 4, pp. 141–147, 2016.

[26] L. Tan, J. Liu, X. Liu et al., "Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting," *Journal of Experimental & Clinical Cancer Research*, vol. 28, no. 1, p. 131, 2009.

[27] H. Kawazoe, R. Uozumi, A. Murakami et al., "Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: a retrospective study," *Scientific Reports*, vol. 8, no. 1, p. 16232, 2018.

[28] K. Matsui, K. Kuriyama, T. Yoshiike et al., "The effect of short or long sleep duration on quality of life and depression: an internet-based survey in Japan," *Sleep Medicine*, vol. 76, pp. 80–85, 2020.

[29] H. B. Wasling, A. Bornstein, and P. Wasling, "Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study," *Sleep Medicine*, vol. 76, pp. 104–112, 2020.

[30] M. Gundog, H. Basaran, O. Bozkurt, and C. Eroglu, "Comparação da dose cumulativa de cisplatina e esquema de tratamento em pacientes com carcinoma nasofaringeo tratados concomitantemente com quimiorradioterapia," *Brazilian Journal of Otorhinolaryngology*, vol. 86, no. 6, pp. 676–686, 2020.